Nanobiotix S.A. NBTX

NBTX Company Overview

Nanobiotix S.A. is a France-based clinical-stage biotechnology company focused on developing nanomedicine therapies designed to improve cancer treatment outcomes. The company operates primarily within the oncology and radiotherapy sectors, with a strategic emphasis on enhancing the effectiveness of radiation therapy through proprietary nanoparticle technology platforms. Its lead product candidate, NBTXR3, is a radioenhancer composed of hafnium oxide nanoparticles that are intended to increase tumor sensitivity to ionizing radiation while limiting damage to surrounding healthy tissue.

The company’s primary revenue drivers currently consist of collaboration agreements, licensing arrangements, and research partnerships, as Nanobiotix has not yet established broad commercial product sales. Nanobiotix serves oncology treatment providers, cancer centers, and biopharmaceutical collaborators across multiple cancer indications, including head and neck cancer, soft tissue sarcoma, lung cancer, and pancreatic cancer. Founded in 2003 in Paris, the company evolved from an early-stage nanotechnology research venture into a publicly traded biotechnology company listed on Euronext Paris and the Nasdaq Global Market under the ticker NBTX. Its positioning is differentiated by its physics-based therapeutic approach that seeks to work across multiple solid tumor indications independent of specific genetic biomarkers.